Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Adma Biologics Inc. (ADMA) Insider Trading Activity
Healthcare • Biotechnology • 624 employees
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Total Value
-$3,274,742.54
Total Shares
283,429
Average Trade Value
-$148,851.93
Most Active Insider
Grossman Adam S
Total Activity: $2,858,008
Largest Single Transaction
$1,033,204
by Grossman Adam S on Nov 22, 2024
30-Day Activity
13 Transactions
Volume: 377,347 shares
Value: $1,255,959
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
President and CEO
|
Feb 26, 2025 | 54,867 | $865,801 | 2,153,801 (-2.5%) | Payment of Exercise Price | |
|
CFO and Treasurer
|
Feb 26, 2025 | 5,280 | $83,318 | 256,380 (-2.1%) | Payment of Exercise Price | |
|
COO and Svp, Compliance
|
Feb 25, 2025 | 1,855 | $28,641 | 522,161 (-0.4%) | Payment of Exercise Price | |
|
President and CEO
|
Feb 25, 2025 | 18,018 | $278,198 | 2,208,668 (-0.8%) | Payment of Exercise Price | |
| Feb 19, 2025 | 10,889 | $0 | 164,830 (+6.6%) | Grant | ||
| Feb 19, 2025 | 10,889 | $0 | 478,194 (+2.3%) | Grant | ||
| Feb 19, 2025 | 10,889 | $0 | 34,929 (+31.2%) | Grant | ||
|
CFO and Treasurer
|
Feb 19, 2025 | 62,227 | $0 | 261,660 (+23.8%) | Grant | |
| Feb 19, 2025 | 10,889 | $0 | 87,330 (+12.5%) | Grant | ||
|
President and CEO
|
Feb 19, 2025 | 252,022 | $0 | 2,226,686 (+11.3%) | Grant | |
|
COO and Svp, Compliance
|
Feb 19, 2025 | 77,784 | $0 | 524,016 (+14.8%) | Grant | |
| Feb 19, 2025 | 10,889 | $0 | 10,889 (+100.0%) | Grant | ||
| Feb 19, 2025 | 10,889 | $0 | 252,330 (+4.3%) | Grant | ||
|
COO and Svp, Compliance
|
Jan 30, 2025 | 5,000 | $54,000 | 449,587 (+1.1%) | Exercise/Conversion | |
|
COO and Svp, Compliance
|
Jan 30, 2025 | 3,355 | $54,016 | 446,232 (-0.8%) | Payment of Exercise Price | |
|
COO and Svp, Compliance
|
Dec 31, 2024 | 1,854 | $31,796 | 444,587 (-0.4%) | Payment of Exercise Price | |
|
President and CEO
|
Dec 31, 2024 | 14,343 | $245,982 | 1,974,664 (-0.7%) | Payment of Exercise Price | |
| Nov 27, 2024 | 9,000 | $97,200 | 2,124,671 (+0.4%) | Exercise/Conversion | ||
|
President and CEO
|
Nov 22, 2024 | 48,967 | $1,033,204 | 1,989,007 (-2.5%) | Sale | |
|
CFO and Treasurer
|
Nov 22, 2024 | 15,000 | $317,250 | 199,433 (-7.5%) | Sale | |
|
President and CEO
|
Sep 30, 2024 | 21,752 | $434,822 | 2,037,974 (-1.1%) | Payment of Exercise Price | |
|
COO and Svp, Compliance
|
Sep 30, 2024 | 2,647 | $52,914 | 446,441 (-0.6%) | Payment of Exercise Price |